Navigation Links
Treatment of retinal conditions appears to have changed significantly in previous decade
Date:10/11/2010

The number of Medicare recipients undergoing treatment for retinal conditions nearly doubled between 1997 and 2007, with significant shifts in the types of procedures most commonly performed, according to a report in the October issue of Archives of Ophthalmology, one of the JAMA/Archives journals.

"Retinal disease is highly prevalent among older individuals, and both age-related macular degeneration (AMD) and diabetic retinopathy account for more than half the irreversible blindness in older Americans. The prevalence of both macular degeneration and diabetic retinopathy increases with age, and the number of Americans affected by these conditions is expected to increase substantially as the number of Americans older than 65 years doubles from 2010 to 2040," the authors write as background information in the article. "The last decade has seen substantial changes in the treatment options available for many retinal diseases, particularly in the treatment of neovascular AMD," a form of the disease involving abnormal blood vessel growth in the eye.

Pradeep Y. Ramulu, M.D., M.H.S., Ph.D., of Wilmer Eye Institute, Johns Hopkins University, Baltimore, and colleagues analyzed Medicare fee-for-service data claims filed between 1997 and 2007. Overall, the number of retinal procedures performed increased 192 percent. Increases occurred each year except between 1997 and 1998; the largest year-to-year increase in volume, 20 percent, occurred between 2006 and 2007.

"Procedure volumes changed most markedly for treatments directed toward neovascular AMD," the authors write. New treatments for this condition include intravitreal therapyinjections of drugs administered directly into the eyeof antibodies that block the formation of new blood vessels. Between 1997 and 2001, fewer than 5,000 such injections were performed each year. However, rates more than doubled each year through 2006, increasing between 2001 (when 4,215 of these procedures were performed) and 2007 (when injections totaled 812,413).

Photodynamic therapy, a laser treatment for neovascular AMD approved in 2000, peaked in 2004 with 133,565 procedures and then decreased 83 percent to 22,675 procedures in 2007. Laser treatment of choroidal lesions (potentially cancerous eye tumors) and neovascular AMD also decreased 83 percent, from a peak of 82,089 in 1999 to 13,821 in 2007.

Vitrectomysurgical removal of the gel inside the eye, used to treat retinal detachmentsincreased 72 percent, from 11,212 in 1997 to 19,923 in 2007. Scleral buckling, a treatment for the same condition involving placing a silicon buckle around the eye, can be performed with or without vitrectomy. Scleral buckling alone became less common during the study period (a 69 percent decrease, from 8,691 to 2,660).

"Observing use patterns adds value, because it demonstrates how disease is treated and can be used to identify possible discrepancies between the best evidence-based treatments for a condition (as defined by clinical trials and meta-analyses from the literature) and current practice patterns," the authors conclude. "In this report, we observe that intravitreal injections of pharmacologic agents have gained widespread acceptance for the treatment of neovascular AMD and that vitrectomy is being increasingly applied to a wide range of retinal conditions."


'/>"/>

Contact: John Lazarou
jlazaro1@jhmi.edu
410-502-8902
JAMA and Archives Journals
Source:Eurekalert

Related medicine news :

1. Despite Treatment, Employees with Depression Generate Higher Absentee Costs, According to Thomson Reuters Study
2. Women More Likely to Fail Treatment for Atrial Fibrillation
3. Social Anxiety and Panic - Alternative Treatment to Drugs and Therapy
4. Neuroimaging study may pave way for effective Alzheimers treatments
5. Nanofilm Introduces Clarity Defog It™ Anti Fog Treatment and EcoClens™ Eco-Friendly Lens Cleaner at Vision Expo East
6. Many veterans not getting enough treatment for PTSD
7. Scott & White Memorial Hospital uses device to revolutionize treatment of traumatic aortic injury
8. Allegheny General Hospital Study Demonstrates Safety and Potential Efficacy of Oral Allergy Treatment
9. Charging less for more effective treatments could reduce health care costs while improving health
10. Added Drug Aids MS Treatment
11. PTSD Treatment Still Lacking for Veterans
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/16/2017)... ... ... Maury Regional Health has announced a large-scale adoption of AccuVein vein visualization ... Regional Medical Center is making vein visualization part of their standard of care. , ... importantly, helps our staff members locate a vein that will provide good access to ...
(Date:8/16/2017)... ... August 16, 2017 , ... A global leader in the treatment ... clinics in all 29 Indian states—bringing the country one step closer to eliminating clubfoot ... the nonprofit organization is on track to enroll 10,000 children in the clubfoot treatment ...
(Date:8/16/2017)... ... , ... Fusion Flix Inc., a Telly Award Winning, Non Profit Corporation has ... viewers in a partnership with the Amazon Video Direct Streaming Distribution Platform. , Their ... Ray disc in 2018. Proceeds will be going to further health research. , ...
(Date:8/16/2017)... (PRWEB) , ... August 16, 2017 , ... TopConsumerReviews.com recently ... Lab Testing . , The healthcare industry in the United States has undergone ... are the days of needing to have a doctor’s order to get a blood ...
(Date:8/16/2017)... , ... August 16, 2017 , ... First Choice ... States, named Dr. Douglas J. Harrison, as the new Medical Director of its Sienna ... new facility Medical Director of our Sienna Plantation location,” said Dr. Michael (Derek) Caraway, ...
Breaking Medicine News(10 mins):
(Date:8/15/2017)... , Aug. 15, 2017  AOTI Inc. announced today that its ... Inc., has recently opened a New York City Office in ... of its unique Topical Wound Oxygen (TWO 2 ) homecare therapy. ... Accreditation Commission for Health Care (ACHC) under the company,s DMEPOS accreditation ... ...
(Date:8/8/2017)... Israel, Aug. 8, 2017  BioLineRx Ltd. (NASDAQ/TASE: BLRX), ... today reports its financial results for the second quarter ... during the second quarter 2017 and to date: ... clinical development programs for the Company,s lead project, BL-8040: ... pivotal study with BL-8040 as novel stem cell mobilization ...
(Date:8/7/2017)... Mich. , Aug. 7, 2017 Diplomat Pharmacy, ... of Joel Saban as president, effective Aug. 7, ... Urick has decided to pursue other interests and will ... "During his tenure, Paul has served us in multiple leadership ... Specialty Pharmacy in Jun. 2015 and has provided decisive, strategic ...
Breaking Medicine Technology: